Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry

[1]  Benjamin N Schneider,et al.  Managing the Risks of ADHD Treatments , 2014, Current Psychiatry Reports.

[2]  P. Arun,et al.  Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder , 2014, Indian Pediatrics.

[3]  S. Stroup,et al.  Pragmatic design in randomized controlled trials , 2014, Psychological Medicine.

[4]  G. Salum,et al.  ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. , 2013, International journal of epidemiology.

[5]  C. Bushe,et al.  Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials , 2013, Child and Adolescent Psychiatry and Mental Health.

[6]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[7]  J. Buitelaar,et al.  Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. , 2013, Journal of child psychology and psychiatry, and allied disciplines.

[8]  B. Rinaldi,et al.  Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. , 2012, Journal of child and adolescent psychopharmacology.

[9]  J. Swanson,et al.  Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. , 2012, The American journal of psychiatry.

[10]  R. Hanwella,et al.  Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis , 2011, BMC psychiatry.

[11]  S. Cortese,et al.  ADHD in adolescents with borderline personality disorder , 2011, BMC psychiatry.

[12]  S. Pliszka,et al.  Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[14]  Bung-Nyun Kim,et al.  Atomoxetine versus Methylphenidate in Paediatric Outpatients with Attention Deficit Hyperactivity Disorder: A Randomized, Double-Blind Comparison Trial , 2007, The Australian and New Zealand journal of psychiatry.

[15]  K. Schuh,et al.  Effects of atomoxetine and methylphenidate on sleep in children with ADHD. , 2006, Sleep.

[16]  T. Wilens,et al.  Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[17]  S. Cortese,et al.  ADHD and insomnia. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  S. Faraone,et al.  Attention-deficit hyperactivity disorder , 2005, The Lancet.

[19]  Joseph Biederman,et al.  The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies , 2005, Psychological Medicine.

[20]  M. Bonati,et al.  Italian attention-deficit/hyperactivity disorder registry. , 2004, Pediatrics.

[21]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[22]  Loudon Jb.  Social anthropology and psychiatry. , 1972 .

[23]  J. Buitelaar,et al.  European clinical guidelines for hyperkinetic disorder – first upgrade , 2004, European Child & Adolescent Psychiatry.

[24]  V. Roessner,et al.  Evaluation of the self-reported SDQ in a clinical setting: Do self-reports tell us more than ratings by adult informants? , 2004, European Child & Adolescent Psychiatry.